Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
2022 | Bevacizumab and atezolizumab as first-line therapy for advanced hepatocellular carcinoma: A Taiwanese subgroup analysis on efficacy and safety | YU-YUN SHAO ; Feng Y.-H.; Yen C.-J.; Yang T.-S.; YING-CHUN SHEN ; Chao Y.; Chen J.-S.; Su C.-Y.; Chen W.-J.; Hsiang H.-L.; CHIH-HUNG HSU | Journal of the Formosan Medical Association | 3 | 4 | |
2013 | Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study | CHIH-HUNG HSU ; Kang Y.K.; Yang T.-S.; CHIA-TUNG SHUN ; YU-YUN SHAO ; Su W.-C.; Sandoval-Tan J.; Chiou T.-J.; Jin K.; CHIUN HSU ; ANN-LII CHENG | Oncology (Switzerland) | 40 | 41 | |
2023 | Cancer-Associated Thrombosis: A Taiwanese Perspective on Therapeutic Options with Focus on Non-Vitamin K Antagonist Oral Anticoagulants | YU-YUN SHAO ; Ho, Ching-Liang; Chang, Cheng-Shyong; Chang, Chia-Lun; JEN-KUANG LEE ; HUNG-JU LIN ; Hsiao, Hui-Hua; Chao, Ta-Chung; Lin, Ching-Yeh; Liaw, Chuang-Chi | Acta Cardiologica Sinica | 1 | 1 | |
2010 | Characteristics and risk factors of oxaliplatin-related hypersensitivity reactions | YU-YUN SHAO ; Hu F.-C.; JIN-TUNG LIANG ; Chiu W.-T.; ANN-LII CHENG ; CHIH-HSIN YANG | Journal of the Formosan Medical Association | 27 | 23 | |
2014 | Clinical activity of metronomic chemotherapy in liver cancers | YU-YUN SHAO ; ANN-LII CHENG ; CHIH-HUNG HSU | Metronomic Chemotherapy: Pharmacology and Clinical Applications | 0 | 0 | |
2014 | Clinical characteristics of advanced hepatocellular carcinoma patients with prolonged survival in the era of anti-angiogenic targeted-therapy | LI-CHUN LU ; YU-YUN SHAO ; Chan S.-Y.; CHIH-HUNG HSU ; ANN-LII CHENG | Anticancer Research | 12 | 10 | |
2015 | Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma | BIN-CHI LIAO ; YU-YUN SHAO ; Chen H.-M.; Shau W.-Y.; ZHONG-ZHE LIN ; Kuo R.N.; Lai C.-L.; KUO-HSING CHEN ; ANN-LII CHENG ; CHIH-HSIN YANG ; Lai M.-S. | Clinical Lung Cancer | 11 | 8 | |
2013 | Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer | YU-YUN SHAO ; Shau W.-Y.; ZHONG-ZHE LIN ; Chen H.-M.; Kuo R.; CHIH-HSIN YANG ; Lai M.-S. | European Journal of Cancer | 20 | 18 | |
2019 | Considerations of heterogeneity in clinical trials for hepatocellular carcinoma | TSUNG-HAO LIU ; YU-YUN SHAO ; LI-CHUN LU ; Ying-Chun Shen ; CHIUN HSU ; ZHONG-ZHE LIN ; CHIH-HUNG HSU ; ANN-LII CHENG | Expert Review of Gastroenterology and Hepatology | 5 | 7 | |
2021 | Correspondence to: Management of venous thromboembolisms: Part II. The consensus for pulmonary embolism and updates | YU-YUN SHAO ; HUNG-JU LIN | Acta Cardiologica Sinica | 2 | 2 | |
2016 | Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression | CHIUN HSU ; LIANG-IN LIN ; Cheng, Yu-Che; Feng, Zi-Rui; YU-YUN SHAO ; ANN-LII CHENG ; DA-LIANG OU | Clinical Cancer Research | 43 | 41 | |
2022 | Cyclin-Dependent Kinase 9 Inhibition as a Potential Treatment for Hepatocellular Carcinoma | YU-YUN SHAO ; Hsu, Hung-Wei; Wo, Rita Robin; Wang, Han-Yu; ANN-LII CHENG ; CHIH-HUNG HSU | Oncology | 3 | 3 | |
2016 | Cytotoxic Chemotherapy as First-Line Therapy for Advanced Non-Small-Cell Lung Cancer in Taiwan: Daily Practice | YI-HSIN LIANG ; YU-YUN SHAO ; BIN-CHI LIAO ; Lee, Ho-Sheng; CHIH-HSIN YANG ; Chen, Ho-Min; CHUN-JU CHIANG ; ANN-LII CHENG ; Lai, Mei-Shu | Journal of Cancer | 8 | 7 | |
2018 | Development of a general method for quantifying IgG-based therapeutic monoclonal antibodies in human plasma using protein G purification coupled with a two internal standard calibration strategy using LC-MS/MS | Chiu, Huai Hsuan; Liao, Hsiao Wei; YU-YUN SHAO ; YEN-SHEN LU ; CHING-HUNG LIN ; Tsai, I. Lin; CHING-HUA KUO | Analytica Chimica Acta | 49 | 45 | |
2012 | Diabetes mellitus is associated with increased mortality in patients receiving curative therapy for hepatocellular carcinoma | Shau W.-Y.; YU-YUN SHAO ; Yeh Y.-C.; ZHONG-ZHE LIN ; Kuo R.; CHIH-HUNG HSU ; CHIUN HSU ; ANN-LII CHENG ; Lai M.-S. | Oncologist | 32 | 32 | |
2023 | Different immune contextures underlie tumor site-specific responses to immune checkpoint blockade in esophageal cancer | JHE-CYUAN GUO ; Hsu, Chia-Lang; MIN-SHU HSIEH ; CHIA-CHI LIN ; TA-CHEN HUANG ; HUNG-YANG KUO ; YU-YUN SHAO ; CHIH-HUNG HSU | Thoracic cancer | 0 | 0 | |
2019 | Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma | LI-CHUN LU ; CHIUN HSU ; YU-YUN SHAO ; Chao Y.; Yen C.-J.; I-LUN SHIH ; Hung Y.-P.; Chang C.-J.; Ying-Chun Shen ; JHE-CYUAN GUO ; TSUNG-HAO LIU ; CHIH-HUNG HSU ; ANN-LII CHENG | Liver Cancer | 46 | 44 | |
2012 | Dissimilar immunohistochemical expression of ERK and AKT between paired biopsy and hepatectomy tissues of hepatocellular carcinoma | YU-YUN SHAO ; Chen C.-L.; MING-CHIH HO ; Huang C.-C.; Tu H.-C.; CHIH-HUNG HSU ; ANN-LII CHENG | Anticancer Research | 9 | 10 | |
2017 | Do-not-resuscitate consent signed by patients indicates a more favorable quality of end-of-life care for patients with advanced cancer | YI-HSIN LIANG ; Wei, C. H.; Hsu, W. H.; YU-YUN SHAO ; Lin, Y. C.; Chou, P. C.; ANN-LII CHENG ; KUN-HUEI YEH | Support Care Cancer | 10 | 10 | |
2021 | Dynamic Contrast-Enhanced and Intravoxel Incoherent Motion MRI Biomarkers Are Correlated to Survival Outcome in Advanced Hepatocellular Carcinoma | BANG-BIN CHEN ; YU-YUN SHAO ; ZHONG-ZHE LIN ; CHIH-HUNG HSU ; ANN-LII CHENG ; CHIUN HSU ; PO-CHIN LIANG ; TIFFANY TING-FANG SHIH | Diagnostics (Basel, Switzerland) | 7 | 7 | |